Editorials

Expanding Medical Marijuana Access in Canada: Considerations for the Rheumatologist
M-A. Fitzcharles, S. Jamal ........................................... 143

Cannabis in the Treatment of Rheumatic Diseases: Suggestions for a Reasoned Approach H. Kalant ................. 146

Lumpers and Splitters: Ongoing Issues in the Classification of Large Vessel Vasculitis P.C. Grayson ........................................... 149

The Need for Preclinical Biomarkers in Systemic Autoimmune Rheumatic Diseases C. Landolt-Marticorena ................................. 152

Obstetric Antiphospholipid Syndrome: Has the Black Swan Swallowed a Red Herring?
C.A. Clark, K.A. Spitzer, C.A. Laskin .................................. 155

Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?
P.L. Meroni, C.B. Chighizola, M. Gerosa, L. Trespidi, B. Acaia .......................................................... 158

Articles

Inhibition of PCSK6 May Play a Protective Role in the Development of RA
F. Wang, L. Wang, H. Jiang, X. Chang, J. Pan ............................. 161

Genetic Polymorphisms of Foxp3 in Patients with RA

Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of RA
X. Deng, C.S. Crowson, S.V. Rajkumar, et al ............................. 181

Cardiovascular Disease-related Hospital Admissions of Patients with Inflammatory Arthritis

Switching from IV to Subcutaneous Formulation of Abarcept: A Single-center Italian Experience on Efficacy and Safety
R. Reggia, F. Franceschini, A. Tincani, I. Cavazzana .......................... 193

Evaluation of Left Atrial Function by Real-time 3-D Echocardiography in Patients with SLE
K. Li, R. Wang, M. Dai, J. Lu, Y. Zou, X. Yang .............................. 196

Elevated Serum Levels of Syndecan-1 Are Associated with Renal Involvement in Patients with SLE

Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia
C. Gonzalez-Echavarri, I. Villar, A. Ugarte, R. Larrieta, G. Ruiz-Iturbe ............................... 210

The Circulating Cell-free microRNA Profile in SSc Is Distinct from Both Healthy Controls and SLE
S.O. Steen, L.V. Iversen, A.L. Carlsten, et al .................................... 214

Association Between Nailfold Capillaroscopy Findings and Pulmonary Function Tests in Patients with SSc
I. Castellvi, C.P. Simeón-Aznar, M. Sarmiento, et al ............................ 222

Trabecular Bone Score in Female Patients with SSc: Comparison with RA and Influence of Glucocorticoid Exposure
E. Koumakis, J. Avouac, R. Winzenrieth, et al ................................. 228

IV Immunoglobulin May Be an Effective Therapy for Refractory, Active Diffuse Cutaneous SSc
C.L. Poelman, L.K. Hummers, F.M. Wigley, C. Anderson, F. Boin, A.A. Shah ........................................... 236

Criterion-concurrent Validity of Spinal Mobility Tests in Ankylosing Spondylitis: A Systematic Review of the Literature
M.P. Castro, S.M. Stebbings, S. Milosavljevic, M.D. Bussey .......................................................... 243

Male Sexual Dysfunction and Ankylosing Spondylitis: A Systematic Review and Metaanalysis
D. Fan, L. Liu, N. Ding, et al .................................................. 252

Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-TNF-α Drugs: An Italian Multicenter Study
E. Lubrano, F.M. Perrotta, A. Marchesoni, et al ................................. 258

Contents continued on page xxii
The Interleukin 33/ST2 Axis in Patients with Primary Sjögren Syndrome: Expression in Serum and Salivary Glands, and the Clinical Association
S.M. Jung, J. Lee, S.Y. Baek, et al .......................... 264

Echocardiographic Abnormalities in New-onset Polymyositis/dermatomyositis
A. Péter, Á. Balogh, S. Szilágyi, et al ......................... 272

Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study
Z. Yang, F. Lin, B. Qin, Y. Liang, R. Zhong .................. 282

PTPN22 R620W Polymorphism and ANCA Disease Risk in White Populations: A Metaanalysis
Y. Cao, K. Liu, Z. Tian, et al ................................ 292

Clinical Features and Radiological Findings in Large Vessel Vasculitis: Are Takayasu Arteritis and Giant Cell Arteritis 2 Different Diseases or a Single Entity?
S. Furuta, C. Cousins, A. Chaudhry, D. Jayne ............ 300

Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort

Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis? Results from a French Population-based Study
G. Pugnet, L. Sailler, R. Bourrel, J-L. Montastruc, M. Lapeyre-Mestre ................................................. 316

Imbalance of Prevalence and Specialty Care for OA for First Nations People in Alberta, Canada
C. Barnabe, B. Hemmelgarn, C.A. Jones, et al .............. 323

The SAPHO Syndrome: A Single-center Study of 41 Adult Patients

Cost of Illness and Determinants of Costs Among Patients with Gout B. Spaetgens, J.M.A. Wijnands, C. van Durme, S. van der Linden, A. Boonen .................. 335

Images in Rheumatology
Dual-energy CT for the Evaluation of Calcinosis in SSc
V. Hsu, M. Bramwit, N. Schlesinger ....................... 345

A Vertebral Bite by an Aneurysm
F. Verhoeven, D. Wendling ................................. 347

Tumoral Calcinosis During the Course of Systemic Sclerosis A. Audemard, N.M. Silva, J. Boutemy, G. Maigné, B. Bienvenu ................. 348

Correspondence
Chemerin and Cardiovascular Risk in RA after Interleukin 6 Receptor Blockade
K. Makrilakis, K. Fragiadaki, P.P. Sfikakis, G.D. Kitas . . . 349

Reply P.H. Dessein, L. Tsang, G.R. Norton, A. Solomon . 349

Comment on “Fibromyalgia and Physical Trauma: The Concepts We Invent”
R. Mader, D. Buskila, M. Ehrenfeld ........................ 351

Reply F. Wolfe ............................................... 352

Meetings in Rheumatology .............................